MQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Marqeta Inc (MQ) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant headwinds, including bearish technical indicators, declining financial performance, and negative sentiment from analysts. While the company has shown revenue growth, its profitability metrics have deteriorated significantly, and there are no strong positive catalysts to suggest an imminent turnaround. Given the lack of strong buy signals from Intellectia Proprietary Trading Signals and the overall negative outlook, it is better to hold off on investing in MQ at this time.
The technical indicators are bearish. The MACD is slightly positive but contracting, RSI is neutral at 38.173, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 3.788, with resistance at 4.216. The pre-market price of 3.84 reflects a -2.04% decline, further indicating weakness.
Revenue increased by 26.75% YoY in Q4 2025, indicating some growth in the company's operations. Additionally, the options market shows bullish sentiment in the short term.
Hedge funds are selling heavily, with a 160.97% increase in selling activity last quarter. Analysts have consistently downgraded the stock and lowered price targets due to concerns about client renewals, pricing pressures, and competition. The company's net income and EPS have significantly declined, and gross margin has contracted. Additionally, news of potential fiduciary breaches could weigh on investor confidence.
In Q4 2025, revenue grew by 26.75% YoY to $172.1 million. However, net income dropped by 94.86% YoY to -$1.39 million, EPS fell to 0 (down 100% YoY), and gross margin contracted by 4.82% YoY to 64.97%. These metrics indicate declining profitability despite revenue growth.
Analysts have a neutral to bearish outlook on MQ. UBS, Morgan Stanley, JPMorgan, Mizuho, and Wolfe Research have all lowered their price targets, citing concerns about client renewals, pricing pressures, and competition. The stock is viewed as a 'show-me story' with guidance risks and uncertainty around its key client relationships.
